Lactobacilli and Bifidobacterium as anti-atherosclerotic agents

被引:2
|
作者
Abdi, Milad [1 ]
Ghaleh, Hadi Esmaeili Gouvarchin [2 ]
Ranjbar, Reza [3 ]
机构
[1] Kerman Univ Med Sci, Res Ctr Trop & Infect Dis, Kerman, Iran
[2] Baqiyatallah Univ Med Sci, Appl Virol Res Ctr, Tehran, Iran
[3] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Mol Biol Res Ctr, Tehran, Iran
关键词
Atherosclerosis; Bifidobacterium; Hypercholesterolemia; Inflammation; Lactobacilli; Oxidative stress; TMAO; TRIMETHYLAMINE N-OXIDE; BILE-SALT HYDROLASE; CHAIN FATTY-ACIDS; LIVER-X-RECEPTOR; CHOLESTEROL-LOWERING EFFICACY; PICK C1-LIKE 1; LIPID PROFILE; OXIDATIVE STRESS; SERUM-CHOLESTEROL; RISK-FACTORS;
D O I
10.22038/IJBMS.2022.63860.14073
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atherosclerosis is the thickening or hardening of the arteries which is caused by a buildup of atheromatous plaque in the inner lining of an artery. Hypercholesterolemia, inflammation, oxidative stress, and trimethylamine N-oxide (TMAO) are important risk factors for atherosclerosis. Therefore, this study aimed to review the anti-atherosclerotic effects of Lactobacilli and Bifidobacterium via improving lipid profile and reducing the effects of oxidative stress, inflammation, and TMAO. To prepare the present review, several databases such as Scopus, PubMed, and Google Scholar were searched, and relevant articles from 1990 until 2022 were selected and reviewed. The present review showed that Lactobacilli and Bifidobacterium reduce the risk of atherosclerosis in both in vitro and in vivo studies by breaking down or altering cholesterol metabolism with the help of their by-products and by reducing inflammation and oxidative stress and TMAO. Consumption of Lactobacilli and Bifidobacterium can be useful in prevention of atherosclerosis.
引用
收藏
页码:934 / 946
页数:13
相关论文
共 50 条
  • [1] New trends in anti-atherosclerotic agents
    Napoli, C
    Sica, V
    Pignalosa, O
    de Nigris, F
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (15) : 1755 - 1772
  • [2] EP 80317 a prototype of a new class of anti-atherosclerotic agents
    Ong, H.
    Harb, D.
    Bujold, K.
    Febbraio, M.
    Tremblay, A. .
    Sirois, M. G.
    Marleau, S.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 256 - 256
  • [3] In search of antioxidants and anti-atherosclerotic agents from herbal medicines
    Shiao, Ming-Shi
    Chiu, Jing-Jing
    Chang, Bao-Wen
    Wang, Jane
    Jen, Wei-Ping
    Wu, Ye-Jer
    Chen, Yuh-Lien
    BIOFACTORS, 2008, 34 (02) : 147 - 157
  • [4] Analysis of anti-apoptotic intracellular viral serpins as anti-atherosclerotic agents
    Liu, LY
    Viswanathan, K
    Dai, EB
    Turner, PC
    Togonu-Bickersteth, J
    Pang, B
    Li, Y
    Moyer, RW
    McFadden, G
    Lucas, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 54A - 54A
  • [5] Emerging Anti-Atherosclerotic Therapies
    Gluba-Brzozka, Anna
    Franczyk, Beata
    Rysz-Gorzynska, Magdalena
    Lawinski, Janusz
    Rysz, Jacek
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [6] Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
    Papanas, N.
    Maltezos, E.
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (27) : 3179 - 3192
  • [7] STUDIES ON ANTI-ATHEROSCLEROTIC AGENTS .2. EXPERIMENTAL STUDIES OF 1,3-PROPANEDIOL BIS(2 PARA CHLOROPHENOXYISOBUTYRATE) (CLY-503) FOR ANTI-ATHEROSCLEROTIC AGENTS
    NAKANISHI, M
    KOBAYAKAWA, T
    OKADA, T
    GOTOH, K
    YAKUGAKU ZASSHI, 1970, 90 (08): : 926 - +
  • [8] Anti-atherosclerotic efficacy of olmesartan
    Miyazaki, M
    Takai, S
    JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (Suppl 2) : S7 - S12
  • [9] Anti-atherosclerotic effects of konjac
    Yanai, Hidekatsu
    Adachi, Hiroki
    Katsuyama, Hisayuki
    Hamasaki, Hidetaka
    Sako, Akahito
    FUNCTIONAL FOODS IN HEALTH AND DISEASE, 2015, 5 (04): : 136 - 144
  • [10] Anti-atherosclerotic efficacy of olmesartan
    M Miyazaki
    S Takai
    Journal of Human Hypertension, 2002, 16 : S7 - S12